Category: Exclusive

Exclusive

Lilly to Conduct HRSA-Approved Audit That Includes First-Time Look for Medicaid MCO Duplicate Discounts

December 19, 2023 Rich Daly, Editor in Chief Views

Eli Lilly is conducting government approved 340B provider audits that for the first time look for certain Medicaid health plan duplicate discounts.

Federal regulators have approved a first-time 340B provider audit by a drug manufacturer to examine processes to prevent duplicate discounts [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Federal 340B Leader Moves On After 21 Months

December 7, 2023 Rich Daly, Editor in Chief Views

U.S. Public Health Service Lieutenant Commander Emeka Egwim left his position as director of OPA at HRSA 21 months after he started.

U.S. Public Health Service Lieutenant Commander Emeka Egwim left his position as director of the federal office overseeing the 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Health Centers Fear Losing 340B Pricing From Sanofi at Multiple Contract Pharmacies

August 29, 2023 Tom Mirga, Editor at Large Views

Changes to Sanofi's 340B drug pricing conditions may eliminate 340B discounts for health centers using multiple contract pharmacies within a chain.

Recent apparent changes to 340B drug pricing conditions by drug manufacturer Sanofi may eliminate 340B discounts for health centers using [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Large Drug Maker, Big Health System, and Influential Health Center Jointly Lobbying for Senate Bipartisan 340B Initiative

July 25, 2023 Tom Mirga, Editor at Large Views

340B Working Table 340B lobbying disclosure form

Under the name 340B Working Table, Genentech, Sanford Health, and Carolina Health Centers are jointly lobbying for a bipartisan U.S. Senate 340B reform initiative.

Biopharmaceutical manufacturer Genentech, South Dakota-based health system Sanford Health, and South Carolina federally qualified health center Carolina Health Centers are jointly lobbying members of Congress to back six U.S. senators’ bipartisan approach to federal 340B program reform, the three organizations

…

HRSA Says COVID Flexibility About Dispensing 340B Drugs in Unregistered Hospital Offsite Locations Will End Thursday

May 8, 2023 Tom Mirga, Editor at Large Views

HRSA has reversed course and will end a 340B COVID-19 flexibility that it previously said was permanent that lets hospitals under certain conditions start using 340B drugs at offsite outpatient locations sooner than HRSA would normally allow.

The U.S. Health Resources and Services Administration said late Friday that when the COVID-19 public health emergency ends on Thursday, so too will a nearly three-year-old policy clarification that lets hospitals under certain conditions dispense 340B drugs at offsite outpatient

…

Exclusive

Lilly to Conduct HRSA-Approved Audit That Includes First-Time Look for Medicaid MCO Duplicate Discounts

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Exclusive

Federal 340B Leader Moves On After 21 Months

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Exclusive

Health Centers Fear Losing 340B Pricing From Sanofi at Multiple Contract Pharmacies

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Exclusive

Large Drug Maker, Big Health System, and Influential Health Center Jointly Lobbying for Senate Bipartisan 340B Initiative

Exclusive

HRSA Says COVID Flexibility About Dispensing 340B Drugs in Unregistered Hospital Offsite Locations Will End Thursday

Site Footer Live